Cabaletta Bio, Inc. (CABA)
Last updated: 2026-10-21 07:09:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Cabaletta Bio, Inc. (CABA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.61, with a market capitalization of $250.93M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.39 to $4.23. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$250.93M | |
$1.51 | |
$26.35 | |
$0.59 | |
$1.48 | |
3.11M | |
4.94M | |
-- | |
$4.23 | |
$1.39 | |
-- | |
-- |
Cabaletta Bio, Inc. (CABA) Latest Closing Stock Price
Cabaletta Bio, Inc. (CABA) last closed at $1.48 as of 2026-10-20 23:59:00, unchanged from the previous close of $1.48.
During the latest regular trading session, CABA traded between $0.59 and $26.35, with a volume of 3.11M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Cabaletta Bio, Inc. (CABA) 7-Day Stock Price Change
Over the past seven days, Cabaletta Bio, Inc. (CABA) moved from $1.79 to $1.61, representing a decline of 10.34% ($0.19).
The stock traded between $1.39 and $1.94 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 5.78 million shares, up versus the previous seven-day period, indicating higher trading activity.
CABA 52-Week Price Position
Position in Range: 7.6%
CABA is currently trading at $1.61, placing it 7.6% of the way from its 52-week low of $1.39 to its 52-week high of $4.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Cabaletta Bio, Inc. (CABA)?
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Cabaletta Bio, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 158 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Cabaletta Bio, Inc. (CABA) Stock on MEXC
Eligible investors can buy real shares of Cabaletta Bio, Inc. (CABA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Cabaletta Bio, Inc. (CABA) stock price today?
2.Is CABA stock going up or down today?
3.What is CABA pre-market price?
4.What is CABA after-hours price?
5.Is CABA stock trading now?
6.Where does CABA sit relative to its 52-week high and low?
7.What sector is Cabaletta Bio, Inc. in?
8.What is Cabaletta Bio, Inc.'s market capitalization and where is it listed?
9.How is CABA valued in terms of P/E ratio and EPS?
10.Does Cabaletta Bio, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CABA Stock Calculator
Estimate the value between CABA shares and USD.
CABA Shares to USD
1.00 CABA shares = 1.605 USD
Calculations are estimates based on the latest available price and are for reference only.


